• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in aspergillus-fumigatus-sensitized mice
 
  • Details
  • Full
Options
2009
Journal Article
Title

Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in aspergillus-fumigatus-sensitized mice

Abstract
Background: Inhibitory effects of roflumilast on responses characteristic of allergic asthma were investigated in a fungal asthma model in BALB/c mice. Methods: Mice were sensitized with Aspergillus antigen (Afu) and exposed to Afu or vehicle, and given roflumilast 1 or 5 mg/kg. Early airway response (EAR) and late airway hyperresponsiveness (AHR) to methacholine were measured via plethysmography. Bronchoalveolar lavage (BAL) was used to assess inflammatory cell count. Results: In Afu-exposed mice, roflumilast dose-dependently reduced the EAR [26% at 1 mg/kg (NS) and 94% at 5 mg/kg (p < 0.01)] and AHR [46% at 1 mg/kg (NS) and 128% at 5 mg/kg (p < 0.05)]. Roflumilast 5 mg/kg reduced neutrophil, eosinophil and lymphocyte counts [87% (p < 0.01), 40% (NS) and 67% (p < 0.01), respectively] in BAL fluid versus controls. Conclusions: In this model, roflumilast inhibited the EAR, suppressed AHR and reduced inflammatory cell infiltration
Author(s)
Hoymann, H.-G.
Wollin, L.
Müller, M.
Korolewitz, R.
Krug, N.
Braun, A.
Beume, R.
Journal
Pharmacology  
DOI
10.1159/000196814
Language
English
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM  
Keyword(s)
  • airway hyperresponsiveness

  • allergic response

  • asthma - mouse

  • chronic obstructive pulmonary disease

  • Phosphodiesterase type 4 inhibitor

  • pulmonary function

  • roflumilast - anti-inflammatory effect

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024